CTNMContineum Therapeutics, Inc.

1. Sep 14, 2026On September 14, 2026, Contineum Therapeutics, Inc. (“Contineum”) issued a press release in which it reported the results of the MOONLIGHT-1 Phase 2 clinical trial evaluating the efficacy, safety, and tolerability of JNJ-5120/PIPE-307 as a monotherapy in adult participants with major depressive disorder.Other event · Form 8-K
2. Jul 30, 2026Key Clinical Development Milestones.Earnings release · press release
3. May 5, 2026Key Clinical Development Milestones.Earnings release · press release
4. Apr 30, 2026On April 30, 2026, the Company announced topline data from its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain. This Phase 1b, randomized, double-blind, placebo-controlled, 4-week, crossover trial enrolled 43 patients (23 chronic osteoarthritic pain (“COAP”) patients and 20 chronic low back pain (“CLBP”) patients)Regulation FD disclosure · Form 8-K
5. Mar 5, 2026As previously reported, on May 14, 2025, the Company entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (“Leerink Partners”), pursuant to which the Company may from time to time issue and sell through Leerink Partners, acting as the Company’s agent, up to $75,000,000 of shares of the …Earnings release · Form 8-K
6. Jan 26, 2026On January 23, 2026, the Board of Directors (the “Board”) of Contineum Therapeutics, Inc. (the “Company”) approved the Continuem Therapeutics, Inc. 2026 Employment Inducement Equity Incentive Plan (the “2026 Inducement Plan”)Director or officer change · Form 8-K
7. Dec 15, 2025On December 11, 2025, Contineum Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an Underwriting Agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC and Leerink Partners LLC, acting as representatives of the several underwriters named in the Underwriting Agreement (the …Material agreement entered · Form 8-K
8. Dec 11, 2025On December 8, 2025, the Company submitted the details of its global Phase 2 clinical trial of PIPE-791 to treat patients with idiopathic pulmonary fibrosis (IPF) to the ClinicalTrials.gov Protocol Registration and Results System (PRS)Other event · Form 8-K
9. Nov 20, 2025On November 20, 2025, Contineum Therapeutics, Inc. issued a press release in which it reported topline data from its Phase 2 PIPE-307 VISTA trial for the treatment of relapsing-remitting multiple sclerosis.Other event · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.